Palantir (PLTR) Rockets 300% on AI Frenzy – Analysts Sound Bubble Alarm

Palantir (PLTR) Rockets 300% on AI Frenzy – Analysts Sound Bubble Alarm

  • Stock Surge: Palantir’s shares have exploded roughly 3× in 2025, trading around $180 as of Oct 20–21, making it one of the year’s top-performing stocks [1] [2]. This rally is far above the S&P 500 and tech peers, propelled by red-hot AI investor enthusiasm.
  • Big AI & Defense Deals: The rally is underpinned by a string of blockbuster contracts. Notable wins include a $10 billion, 10-year U.S. Army IDIQ agreement, a £750–£1,500 million UK defense/AI partnership, a “game-changing” AI integration deal with Boeing Defense, plus new commercial AI tie-ups (e.g. a Snowflake AI-data partnership and OneMedNet healthcare deal) [3] [4]. These deals highlight Palantir’s deepening role in both government and enterprise AI.
  • Record Financials: Palantir’s fundamentals are finally catching up. Q2 2025 revenue jumped 48% YoY to ~$1.03 billion (its first $1B+ quarter) with $327 million GAAP profit, prompting management to raise 2025 revenue guidance to roughly $4.14–4.15 billion [5] [6]. U.S. government sales surged (42% of revs), and free cash flow is strong. Q3 guidance (~$1.083 billion) suggests growth is expected to continue [7] [8].
  • Extreme Valuation: At ~$180 per share, Palantir’s market cap nears $400 billion, with forward price/sales >100× and P/E >200×, among the highest in market history [9] [10]. By comparison, veteran AI chipmaker Nvidia trades in the 20s P/S. Critics warn these “unsustainable” multiples mean the stock is pricing in almost all future growth [11] [12].
  • Analyst Split & Targets: Wall Street is deeply divided. Bulls (e.g. Wedbush’s Dan Ives) hail Palantir as an “AI arms dealer” and see the boom as just beginning; Wedbush even envisions a $1 trillion market cap in the next few years [13]. Piper Sandler recently raised its 12-month price target to $201 (Overweight) [14]. In contrast, skeptics (including short‑seller Citron) call the valuation “absurd”, pegging fair value near ~$65–$70 [15]. Overall the consensus rating remains “Hold,” with targets ranging widely (roughly $100–$215, median ~$150–160 [16] [17]).
  • Bubble Concerns: Many market watchers now warn of an AI-fueled bubble. A Bank of America survey found AI stocks listed as the top global risk, and analysts note that tech valuations are at euphoric levels [18] [19]. Investing.co.uk analyst Christian Harris cautions that PLTR, trading at “over 200 times earnings,” could be among the first to fall if the AI buzz cools [20] [21].

With Q3 earnings (Nov. 3) looming, investors will watch whether Palantir can sustain this torrid pace or if profit-taking ensues. The company’s defense and AI momentum is real – Saxo’s Jacob Falkencrone notes Palantir is “becoming an indispensable partner for enterprises in the AI revolution” [22] – but the stock’s stratospheric run also leaves little margin for error. As one strategist put it, “the stock is trading at what is frankly an absolutely wild valuation”, so any slowdown or market rotation could trigger a sharp pullback [23].

Sources: Recent reports from TechStock² (TS2) and Reuters detail Palantir’s massive AI/defense contracts and financial beats [24] [25]. Analyst commentary comes from Reuters and Quartz interviews [26] [27]. All data is current as of late Oct. 2025.

Yan: Palantir has the potential to become the operating system for AI

References

1. ts2.tech, 2. ts2.tech, 3. ts2.tech, 4. ts2.tech, 5. ts2.tech, 6. www.reuters.com, 7. www.gurufocus.com, 8. www.reuters.com, 9. ts2.tech, 10. www.reuters.com, 11. ts2.tech, 12. www.reuters.com, 13. www.reuters.com, 14. ts2.tech, 15. ts2.tech, 16. ts2.tech, 17. ts2.tech, 18. ts2.tech, 19. qz.com, 20. qz.com, 21. www.reuters.com, 22. www.reuters.com, 23. qz.com, 24. ts2.tech, 25. www.reuters.com, 26. www.reuters.com, 27. qz.com

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Cogent Biosciences Prices Public Offerings of Common Stock and Convertible Notes for ~$475 Million
    November 12, 2025, 12:38 AM EST. Cogent Biosciences priced a public offering of 9,677,420 shares of common stock at $31.00 and a $200 million aggregate principal amount of 1.625% convertible senior notes due 2031, targeting net proceeds around $475.3 million. The Equity Offering includes a 30-day over-allotment option for up to 1,451,613 additional shares; the Convertible Notes Offering has a corresponding option up to $30 million principal amount to cover over-allotments. Closings are expected Nov. 13, 2025 (equity) and Nov. 18, 2025 (notes). The notes are unsecured senior obligations, with semi-annual interest of 1.625% and an initial conversion rate of 22.2469 shares per $1,000 principal (roughly $44.95 per share).
Hungarian Astronaut Builds Super-Muscles with Futuristic EMSCULPT NEO Device
Previous Story

Hungarian Astronaut Builds Super-Muscles with Futuristic EMSCULPT NEO Device

GE Vernova Stock Poised for Explosive Rally After $5.3B Deal and AI-Powered Energy Boom
Next Story

GE Vernova Stock Poised for Explosive Rally After $5.3B Deal and AI-Powered Energy Boom

Go toTop